ROS1 Expression Correlates With Inguinal Lymph Node Affection in Vulvar Cancer Patients: A Retrospective Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.71160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Meletios P Nigdelis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center (UKS), Homburg, Germany. Hauptthemen laut MEDLINE: Vulvar Neoplasms, Proto-Oncogene Proteins, Protein-Tyrosine Kinases, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Systemic treatment options for vulvar squamous cell carcinoma (VSCC) are limited. ROS1, a tyrosine kinase implicated, for example, in non‐small cell lung cancer (NSCLC), has recently shown responsiveness to tyrosine kinase inhibitors. This study investigated immunohistochemical ROS1 expression in VSCC to explore its potential as a future therapeutic target in this rare malignancy.
Methods
In this retrospective study, 48 patients with VSCC undergoing vulvectomy were included. Clinicopathological data were collected in a standardized manner. Immunohistochemistry (IHC) was used to assess ROS1 expression on an ordinal scale from 0 (absent staining) to 3 (> 50% of neoplastic cells demonstrated cytoplasmatic staining); levels 0 and 1 were considered negative, while 2 and 3 were rated as positive. After differences and correlations with clinicopathological parameters were evaluated between positive and negative tumors, we fitted logistic regression and survival models to assess the association of ROS1 with inguinal lymph node involvement and overall survival. Statistical analysis was conducted using GraphPad and Jamovi.
Results
ROS1 IHC levels were associated with lymph node involvement [odds ratio (OR) 2.396, 95% confidence interval (CI) 1.034–5.555, logistic regression, p = 0.042]. ROS1 positive tumors demonstrated no difference in overall survival compared with negative ones [hazards ratio (HR) 0.837, 95% CI 0.283–2.479, log‐rank (Mantel‐Cox) test, p = 0.738].
Conclusion
ROS1 expression was associated with inguinal lymph node involvement but not overall survival among VSCC patients. Further studies are required to elucidate the role of ROS1 in VSCC therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center (UKS), Homburg, Germany.
- Department of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), Homburg, Germany.
- Saarland University Medical Center for Tumor Diseases (UTS), Homburg, Germany.
- Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
- Saarland Cancer Registry, Saarbrücken, Germany.
ORCID-Profile: Annick Bitterlich
Zitieren
APA
Nigdelis, M. P., Bitterlich, A., Parvanta, M., Haj Hamoud, B., Solomayer, E. F., Ertz, M., Schnöder, L., Hasenburg, A., Holleczek, B., Wagner, M., & Klamminger, G. G. (2025). ROS1 Expression Correlates With Inguinal Lymph Node Affection in Vulvar Cancer Patients: A Retrospective Study. Cancer Medicine. https://doi.org/10.1002/cam4.71160
Vancouver
Nigdelis MP, Bitterlich A, Parvanta M, Haj Hamoud B, Solomayer EF, Ertz M, et al. ROS1 Expression Correlates With Inguinal Lymph Node Affection in Vulvar Cancer Patients: A Retrospective Study. Cancer Medicine. 2025. doi:10.1002/cam4.71160
BibTeX
@article{Nigdelis2025,
author = {Nigdelis, Meletios P and Bitterlich, Annick and Parvanta, Mariam and Haj Hamoud, Bashar and Solomayer, Erich Franz and Ertz, Martin and Schnöder, Laura and Hasenburg, Annette and Holleczek, Bernd and Wagner, Mathias and Klamminger, Gilbert Georg},
title = {ROS1 Expression Correlates With Inguinal Lymph Node Affection in Vulvar Cancer Patients: A Retrospective Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71160}
}
EUVIMED